Novartis Stock Surges 5% Following Positive Phase 3 MS Trial Results

Key Facts

1Novartis stock jumped 5%, marking its best daily performance since 2023 following successful clinical trial results.

2The Phase 3 REMODEL trial for remibrutinib showed positive results in relapsing MS with no liver safety signals.

In a move reflecting optimism over pharmaceutical innovation, Novartis stock jumped 5%, marking its strongest daily performance since 2023. This surge followed the company's announcement of positive results from the Phase 3 REMODEL trial for remibrutinib, a candidate for treating relapsing multiple sclerosis. According to reports, the trial met its primary endpoints and demonstrated promising clinical outcomes.

The results are particularly significant as the drug showed no liver safety signals, addressing a major concern that has historically impacted this class of treatments within the healthcare sector. Per market data, investors reacted bullishly to this development, which removes a key safety overhang from the company's pipeline and strengthens its competitive position in the MS treatment market.

At the close of August 31, 2026, the NVS ticker stood at $152.06, while NVSEF closed at $145.01. With no major upcoming catalysts directly related to the pharmaceutical sector in the immediate calendar, traders will be watching for price consolidation following this spike, alongside any further updates regarding regulatory filing timelines.